ライフサイエンスコーパス: atypical ductal hyperplasia

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 res were age and HRL histologic results (eg, atypical ductal hyperplasia).

2 sis, radial scar, fibroadenoma, and areas of atypical ductal hyperplasia.

3 .5 (95% CI, 0.4 to 5.6) for the diagnosis of atypical ductal hyperplasia.

4 quantitatively insufficient is described as atypical ductal hyperplasia.

5 Atypical ductal hyperplasia ([1.48 +/- 0.36] x 10(-3) mm

6 CNB results in patients with a diagnosis of atypical ductal hyperplasia (ADH) (75 of 6,081 [1.2%]) w

7 ose To assess the rate of underestimation of atypical ductal hyperplasia (ADH) and ductal carcinoma i

8 terozygosity (LOH) on 11q13 (PYGM, INT-2) in atypical ductal hyperplasia (ADH) and various histologic

9 lpable breast lesions diagnosed initially as atypical ductal hyperplasia (ADH) by core needle biopsy.

10 core biopsy revealed carcinoma in 19 (61%), atypical ductal hyperplasia (ADH) in eight (26%), and be

11 osis in two, papilloma with adjacent foci of atypical ductal hyperplasia (ADH) in eight, and well-dif

12 Atypical ductal hyperplasia (ADH) is a known risk factor

13 ision was advised for the 143 carcinomas, 25 atypical ductal hyperplasia (ADH) lesions, and five radi

14 Atypical ductal hyperplasia (ADH) underestimates were le

15 uctal carcinoma in situ (DCIS), one focus of atypical ductal hyperplasia (ADH), and one atypical lobu

16 , such as simple ductal hyperplasia (SH) and atypical ductal hyperplasia (ADH), are candidate precurs

17 Three yielded atypical ductal hyperplasia (ADH); one, residual LCIS; a

18 ncreased expression of 14-3-3 zeta begins at atypical ductal hyperplasia, an early stage of breast di

19 uctal carcinoma in situ were reclassified as atypical ductal hyperplasia and considered false-positiv

20 sed in noninvasive breast lesions, including atypical ductal hyperplasia and ductal carcinoma in situ

21 High-risk lesions (atypical ductal hyperplasia and lobular neoplasia) showe

22 ns (ductal and lobular carcinoma in situ and atypical ductal hyperplasia), and 277 controls without t

23 ative, although premalignant lesions such as atypical ductal hyperplasia are highly ER-alpha-positive

24 %), CCL with atypia 9% (95% CI: 5%-14%), and atypical ductal hyperplasia associated with CCL 20% (95%

25 s of CCL without atypia, CCL with atypia and atypical ductal hyperplasia associated with CCL followed

26 with a CNB diagnosis of CCL with atypia and atypical ductal hyperplasia associated with CCL, surgica

27 A high-risk lesion (ie, atypical ductal hyperplasia, atypical lobular hyperplasi

28 best-characterized premalignant lesions are atypical ductal hyperplasia, atypical lobular hyperplasi

29 Atypical ductal hyperplasia diagnosed via excisional bio

30 20%) yielded high-risk lesions, including 21 atypical ductal hyperplasia, eight atypical lobular hype

31 development of premalignant lesions such as atypical ductal hyperplasia, elevated growth factors, or

32 benign results: fibrocystic changes in four, atypical ductal hyperplasia in two, atypical lobular hyp

33 Atypical ductal hyperplasia is a lesion with significant

34 Two (25%) of eight atypical ductal hyperplasia lesions were upgraded to DCI

35 were either malignant or high-risk lesions (atypical ductal hyperplasia, lobular carcinoma in situ,

36 situ (n = 1), lobular neoplasia (n = 1), or atypical ductal hyperplasia (n = 1).

37 women with atypical lobular hyperplasia plus atypical ductal hyperplasia, the ratio was 1/1.

38 Atypical ductal hyperplasia was found in 23 (4.5%) of 51

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。